Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

See the original article here:
Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share